Company Participants Conference Call Participants These data provided clinical evidence demonstrating for the first time that targeting DGAT2 to reduce hepatic fat production can improve NASH histological endpoints, including improving fibrosis. Study met its primary and key secondary endpoints while also demonstrating that ION224 was safe and well tolerated. These results support advancing this program to the next stage of development. Additionally, we aim to build meaningful relationships with patients an ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.91%. A quarter ago, it was expected that this drug discovery and development company would post a loss of $0.78 per share when it actually produced a loss of $0.06, delivering a surprise of 92.31%.Over the last fo ...

Wall Street analysts expect Ionis Pharmaceuticals (IONS) to post quarterly loss of $1.10 per share in its upcoming report, which indicates a year-over-year decline of 26.4%. Revenues are expected to be $131.51 million, up 0.4% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 1.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's ea ...

The market expects Ionis Pharmaceuticals (IONS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be ...

Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern TimeCARLSBAD, Calif., April 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three ...

–         Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – –         Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S. – –         Data presented today at ACC 2024 and published in The New England Journal of Medicine – –         Ionis to host webcast on Mond ...

CARLSBAD, Calif., April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 20242024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024BofA Securities Health Care Conference 2024 on Tuesday, May 14, 202445th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 12, 2024A live webcast ...

Ionis Pharmaceuticals (IONS) announced positive results from a phase II study on its investigational drug ION224 in adult patients with metabolic dysfunction-associated steatohepatitis (MASH) over 51 weeks.Study participants who received 90mg and 120mg doses of ION224 achieved the primary endpoint of statistically significant liver histologic improvement. This was measured by at least a two-point reduction in the non-alcoholic fatty liver disease (NAFLD) activity score, or NAS. A subgroup analysis indicated ...

Significant improvement in steatohepatitis with >2 point improvement in NAS score without worsening fibrosis, the primary endpoint of the study Achieved key secondary endpoint of MASH resolution without worsening of fibrosis More ION224 treated patients had an improvement of >1 stage fibrosis compared to placebo ION224 was safe and well-tolerated in this study with once-monthly subcutaneous dosing CARLSBAD, Calif., March 13, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positiv ...

Kyle Jenne rejoins company to lead commercial strategy Onaiza Cadoret-Manier departing for new career opportunity With broad commercial capabilities in place, Ionis ready to execute on its first independent launches CARLSBAD, Calif., Feb. 29, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis as executive vice president, chief global product strategy officer, to lead all aspects of commercialization at the Company. Mr. Jenne has more than 25 ye ...